Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
TP, I would wager a hefty sum that Ms Li’s business will go the way of quite a few other Dragons Dens offerings; lots of sparkle, but little substance. Everyone is a professional genius on LinkedIn it seems these days. But do they have staying power? …Time will tell.
And yet, still allowed to post here, ne'er banned no matter the content?
Strange one Aether.
I imagine the LSE Admins must know why that is....?
your last 3 posts get my 'seal' of approval, doc.dan.
i like it when you switch into idyllic, pastoral mode, it's so much more affable. it almost warms the ****les of my heart...
i bid you all a happy friday, may news come soon.
"Biotechnology in 2024
The biotechnology sector is not completely immune to the slings and arrows of broader investor sentiment, but there are some sector-specific reasons for optimism. Despite the recent rally, the Nasdaq Biotechnology Index remains almost 20% below the peak it reached in 20211. This suggests significant upside potential for the index as a whole as we move through 2024 and beyond. This potential is underpinned by the sector’s accelerated pace of innovation, and heightened competitiveness and efficiency, following three years of consolidation and restructuring.
As the chart below demonstrates, the number of new drug approvals is currently high and on an upward trend. Importantly, many of these new therapies are for medical conditions that have previously been considered untreatable. This reflects the accelerating pace of innovation in biotechnology and other scientific fields, and hints at the scale of the opportunity that lies ahead for investors in the sector.
Meanwhile, the prospect of further merger & acquisition (M&A) activity looks strong. Patent expiries among the larger pharma players continues to be a pressing issue and they will continue to look towards the biotech sector for opportunities to plug the holes in their product shelves and pipelines. The continued implementation of the Inflation Reduction Act (IRA) could amplify this demand for the more innovative biotech businesses with promising pipelines, as we explained here in a previous blog. Moreover, if interest rates decline, companies will find it easier to finance deals and product development. In turn, this could lead to a return of initial public offerings (IPOs), signalling an improved sentiment towards the sector."
https://www.schroders.com/en-gb/uk/intermediary/content/what-to-expect-from-biotech-in-2024/
"Biotech funding optimism rises as 44% predict recovery in 2024"
https://www.pharmaceutical-technology.com/analyst-comment/biotech-funding-optimism-rises/#:~:text=Venture%20financing%20for%20US%2Dheadquartered,that%20year%20with%20inflated%20valuations.
A few observations:
"another global crisis on the horizon". Subjective. According to PwC, the deal totals for this Biotech industry in 2024 could range from $225 billion to $275 billion potentially allowing a biotech recovery this year. This robust activity is indicative of the sector's resilience and adaptability in the face of economic challenges and market fluctuations.
What we can say with confidence is that there is certainly another pandemic looming ahead of us, how far out is anyone's guess...
There is no regulation that stipulates that a CEO must update shareholders on a quarterly basis. If you're not happy with the lack of handholding don't invest. No one owes you anything.
We already have 20+ years development behind us - all of that data will not be 'unseen' by BP. The hard slog has already been done. What remains now is highly debateable. Which brings me to my next point;
There is NO guarantee that the company will prioritise a P2 over a lucrative deal if it finds it's way to the table sooner, despite what SS allegedly said a year ago. I would argue that all signs now are that they are doing something pretty secretive as we type...
The process and timelines are not surprising, and have not scared the horses at TFG HQ. If anything, it seems to have eagered them into accumulating ore since Sprinter, which is interesting.
I tend to agree; clarity should arrive soon.
Ah. I wasn't aware TD. I thought you were hinting at a GSK/SNG tie-up. Now that would be interesting...
"GSK's CEO".
A freudian slip, perhaps.... TD?
Such a theatrical poster is DocDan. I feel as if I am immersed in the pages of some distant high seas drama, like The Onedin Line...
20 years? 2 years?
You're surely having a joke Trinity. Or maybe a slip o' the tongue?
I see Sir SH has been busy. Let's hope for news soon.
Interesting concept; suggesting to remove a CEO for doing their job, without the backing or support of the main shareholder. How might you achieve your goal?
What a mess.
Must really muck up your scheduling of the Olivetti keyboard. Still, keeps you on your toes. You never know when news will drop?
Slow day at Citadel/M&A (delete as appropriate) HQ?
It must get rather crowded on that Olivetti keyboard.
Indeed, outstanding in your field, of parsnips.
I do. I can't imagine anyone being so negative about a stock from the very moment they claim to have bought it. Except for you of course. And Mani. And DocDan. And Axe. Plus Andybe4yo. Then there's Org of course, the delightful if historically-confused Sakura...
I could go on...Too many to name...
"This really is a tough share to be involved with." said the bloke with no involvement whatsoever in the share.
All the lolz today. Mani talking to himself in character as Costas, rinse, repeat.
Yawn.
Wonder where you heard that news Mani?
You're a real man of genius, Professionale, that's why I posted the video below. Reminds me of you.